The Effect of Doxazosin, Finasteride and Combination Therapy on Nocturia in Men With Benign Prostatic Hyperplasia

Journal of Urology

Volumn 178, Issue 5, 2007, Pages 2045-2051

  Johnson II, Theodore M ^a,b,c   Burrows, Pamela K ^d   Kusek, John W ^e   Nyberg, Leroy M ^e   Tenover, J Lisa ^b   Lepor, Herbert ^f   Roehrborn, Claus G ^g  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

adrenergic alpha antagonists; finasteride; nocturia; prostatic hyperplasia

Indexed keywords

DOXAZOSIN; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NOCTURIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SELF REPORT; STATISTICAL ANALYSIS; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DOXAZOSIN; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NOCTURIA; PILOT PROJECTS; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URODYNAMICS;

EID: 35148879015     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.07.013     Document Type: Article

References (20)

1. van Kerrebroeck P., Abrams P., Chaikin D., Donovan J., Fonda D., Jackson S., et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 179
2. Weiss J.P., and Blaivas J.G. Nocturia. Curr Urol Rep 4 (2003) 362
3. DuBeau C.E., Yalla S.V., and Resnick N.M. Implications of the most bothersome prostatism symptom for clinical care and outcomes research. J Am Geriatr Soc 43 (1995) 985
4. Gourova L.W., van de Beek C., Spigt M.G., Nieman F.H., and van Kerrebroeck P.E. Predictive factors for nocturia in elderly men: a cross-sectional study in 21 general practices. BJU Int 97 (2006) 528
5. Nishino Y., Masue T., Miwa K., Takahashi Y., Ishihara S., and Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 97 (2006) 747
6. Johnson II T.M., Jones K., Williford W.O., Kutner M.H., Issa M.M., and Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 170 (2003) 145
7. Lepor H., Williford W.O., Barry M.J., Brawer M.K., Dixon C.M., Gormley G., et al., Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335 (1996) 533
8. McConnell J., Roehrborn C., Bautista O., Andriole G.J., Dixon C., Kusek J., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
9. Bautista O.M., Kusek J.W., Nyberg L.M., McConnell J.D., Bain R.P., Miller G., et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 24 (2003) 224
10. Barry M.J., Fowler Jr. F.J., O'Leary M.P., Bruskewitz R.C., Holtgrewe H.L., Mebust W.K., et al., The Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148 (1992) 1549
11. Wein A. Editorial comment. J Urol 175 (2006) 1434
12. Drach G., Ignatoff J., and Layton T. Peak urinary flow rate: observations in female subjects and comparison to male subjects. J Urol 122 (1979) 215
13. Tikkinen K.A., Tammela T.L., Huhtala H., and Auvinen A. Is nocturia equally common among men and women?. A population based study in Finland. J Urol 175 (2006) 596
14. Kaplan S.A., Roehrborn C.G., Rovner E.S., Bavendam T., and Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 296 (2006) 2319
15. Debruyne F.M., Witjes W.P., Fitzpatrick J., Kirby R., Kirk D., Prezioso D., and The ITT Group. The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur Urol 30 (1996) 369
16. Abrams P., and Klevmark B. Frequency volume charts: an indispensable part of lower urinary tract assessment. Scand J Urol Nephrol suppl 179 (1996) 47
17. Matzkin H., Greenstein A., Prager-Geller T., Sofer M., and Braf Z. Do reported micturition symptoms on the American Urological Association Questionnaire correlate with 24-hour home uroflowmetry recordings?. J Urol 155 (1996) 197
18. Blanker M.H., Bohnen A.M., Groeneveld F.P., Bernsen R.M., Prins A., and Ruud Bosch J.L. Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men. J Urol 164 (2000) 1201
19. Johnson II T.M., Sattin R.W., Parmelee P., Fultz N.H., and Ouslander J.G. Evaluating potentially modifiable risk factors for prevalent and incident nocturia in older adults. J Am Geriatr Soc 53 (2005) 1011
20. Abraham L., Hareendran A., Mills I.W., Martin M.L., Abrams P., Drake M.J., et al. Development and validation of a quality-of-life measure for men with nocturia. Urology 63 (2004) 481